Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Press Release|Articles|September 18, 2025
ACRO Issues Comments to CMS on Proposed Rules
Author(s)ACRO
As noted in the letters, "ACRO’s comments seek to ensure ongoing access to high-quality, state-of-the-art radiation oncology services."
Advertisement
ACRO has submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule for the CY 2026 Physician Fee Schedule (CMS-1832-P), as well as the CY 2026 Hospital Outpatient Prospective Payment System Proposed Rule (CMS-1834-P).
The first letter (CMS-1832-P) offers comments and recommendations on the following issues:
- Appropriate APC Placement for Treatment Delivery Codes (77402, 77407, 77412)
- Use of OPPS data to set PFS rates
- Updates to the Indirect Practice Expense (PE) Methodology
- Removal of 77427 from the Telehealth List
- Undervaluation of conversion factor due to G2211 Assumption
- Efficiency Adjustment
- Valuation of Imaging Guidance for Proton Beam Treatment Delivery (CPT codes 77520, 77522, 77523, and 77525)
The second letter (CMS-1834-P) offers comments on:
- Appropriate APC Placement for Treatment Delivery Codes (77402, 77407, 77412)
- BgRT
Advertisement
Related to this article
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5